Aethlon Medical (NASDAQ:AEMD) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report released on Tuesday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright cut their price target on Aethlon Medical from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, June 24th.

Aethlon Medical Price Performance

Shares of NASDAQ AEMD opened at $0.38 on Tuesday. Aethlon Medical has a 1-year low of $0.24 and a 1-year high of $2.35. The business has a 50-day moving average of $0.41 and a 200-day moving average of $0.66. The company has a market capitalization of $5.33 million, a price-to-earnings ratio of -0.08 and a beta of 1.74.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.10. During the same period last year, the firm posted ($1.30) earnings per share. Research analysts expect that Aethlon Medical will post -1.1 EPS for the current fiscal year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.